Australia's Noxopharm climbs after dual-cell therapy shows positive results

Noxopharm

14/09/2022 04:06

** Shares of Noxopharm  NOX.AX  rise as much as 6.7% to
A$0.320, on track for fourth consecutive session of gains 
    ** The drug developer says it has conducted an 18-month
study as part of an ongoing collaboration with the University of
New South Wales, Sydney, to test a new drug developed by the
company, known as CRO-67  urn:newsml:reuters.com:*:nASX8fd4jT
    ** Says major findings were that CRO-67 killed tumour cells
as well as barrier cells in samples taken from six patients who
had their tumours surgically removed
    ** About 974,568 shares change hands compared with 272,548
shares 
    ** Stock down ~23.1% this year, as of last close  

 (Reporting by Tejaswi Marthi in Bengaluru)
 ((tejaswi.marthi@thomsonreuters.com))